Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.
600613.SS · SHH
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 2.39B | 1.26B | 65.85M | 48.55M | 0.09 |
| 2023 FY | 2.34B | 1.15B | 82.84M | 57.00M | 0.11 |
| 2024 FY | 2.05B | 951.71M | 91.67M | 71.39M | 0.13 |
| 2025 FY | 1.95B | 880.69M | 110.77M | 38.24M | 0.07 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 3.38B | 1.01B | 656.49M | 285.61M | 2.33B |
| 2023 FY | 3.28B | 888.77M | 715.28M | 253.07M | 2.34B |
| 2024 FY | 3.12B | 689.01M | 779.39M | 167.06M | 2.36B |
| 2025 FY | 3.15B | 747.59M | 594.09M | 162.82M | 2.32B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 319.23M | -26.64M | 292.59M | -53.45M | 160.82M |
| 2023 FY | 215.59M | -24.51M | 191.08M | -66.29M | 59.72M |
| 2024 FY | 207.79M | -36.39M | 171.39M | -64.18M | 65.10M |
| 2025 FY | 124.47M | -33.22M | 91.26M | -88.22M | -185.30M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 4.44B | 4.07B | — | — | — |
| 2023 FY | 3.94B | 3.48B | — | — | — |
| 2024 FY | 3.77B | 3.15B | — | — | — |
| 2025 FY | 3.32B | 2.89B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 480.92M | 217.60M | 25.26M | 17.81M | 0.03 |
| 2025 Q3 | 437.01M | 215.73M | 20.12M | 17.49M | 0.03 |
| 2025 Q4 | 554.51M | 222.90M | 44.51M | -12.06M | -0.02 |
| 2026 Q1 | 422.94M | 190.88M | 20.42M | 12.88M | 0.02 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 3.00B | 614.48M | 681.53M | 152.58M | 2.31B |
| 2025 Q3 | 3.09B | 676.78M | 611.09M | 194.05M | 2.33B |
| 2025 Q4 | 3.15B | 747.59M | 594.09M | 162.82M | 2.32B |
| 2026 Q1 | 3.04B | 640.98M | 482.37M | 90.19M | 2.33B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 76.25M | -5.03M | 71.22M | -82.98M | -93.68M |
| 2025 Q3 | 109.83M | -6.99M | 102.84M | — | -70.45M |
| 2025 Q4 | -32.83M | -8.57M | -41.40M | -1.48M | -17.00M |
| 2026 Q1 | 41.57M | -3.75M | 37.83M | -1.62M | -128.72M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 3.84B | 3.31B | — | — | — |
| 2025 Q3 | 3.56B | 3.14B | — | — | — |
| 2025 Q4 | 3.28B | 2.85B | — | — | — |
| 2026 Q1 | 3.23B | 2.84B | — | — | — |